Neurosterix raised $63M in a Series A funding led by Perceptive Xontogeny Venture Fund II to advance allosteric modulator therapeutics for neurological disorders.
Neurosterix raised $63M in a Series A funding led by Perceptive Xontogeny Venture Fund II to advance allosteric modulator therapeutics for neurological disorders.
04/03/24, 5:12 AM
Location
new yorkMoney raised
$63 million
Industry
therapeutics
pharmaceutical
biotechnology
health care
Round Type
series a
Investors
Acorn Bioventures, Perceptive Life Sciences Fund, Perceptive Xontogeny Venture Fund Ii
Neurosterix launched with a $63 million Series A financing led by Perceptive Xontogeny Venture Fund II, with participation from Perceptive Life Sciences Fund and Acorn Bioventures. Neurosterix is leveraging decades of investment made by Addex in building a leading allosteric modulator discovery technology platform.
Company Info
Location
new york, new york, united states
Additional Info
Neurosterix is a biopharmaceutical company focused on developing allosteric modulators for the treatment of patients suffering from neurological disorders. Allosteric modulators increase or decrease the activity of target receptors by binding outside of the “active site” where traditional drugs operate. This approach can improve upon the efficacy and tolerability of existing treatments and potentially address new targets to bring therapeutic innovation to existing or new underserved patient communities. Neurosterix is supported by an industry-leading allosteric modulator drug discovery and development platform. For more information, visit neurosterix.com.